PE20210371A1 - Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias - Google Patents
Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemiasInfo
- Publication number
- PE20210371A1 PE20210371A1 PE2020002097A PE2020002097A PE20210371A1 PE 20210371 A1 PE20210371 A1 PE 20210371A1 PE 2020002097 A PE2020002097 A PE 2020002097A PE 2020002097 A PE2020002097 A PE 2020002097A PE 20210371 A1 PE20210371 A1 PE 20210371A1
- Authority
- PE
- Peru
- Prior art keywords
- composition
- weight
- amino acid
- peptide
- treatment
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 208000034737 hemoglobinopathy Diseases 0.000 title abstract 2
- 208000002903 Thalassemia Diseases 0.000 title 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 title 1
- 235000001014 amino acid Nutrition 0.000 abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 abstract 3
- 229960004308 acetylcysteine Drugs 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0606—Arginine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0612—Carnitine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/062—Glutamine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0624—Histidine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0628—Leucine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/063—Lysine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0634—N-Acetyl-Cysteine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0642—Serine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/06—Amino acid
- A23V2250/0654—Valine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
SE REFIERE A UNA COMPOSICION QUE COMPRENDE: A) L-LEUCINA; B) L-ARGININA; C) L-GLUTAMINA; D) N-ACETILCISTEINA (NAC); E) L-CITRULINA; F) L-CARNITINA; G) L-SERINA; H) L-VALINA; I) L-HISTIDINA; J) L-LISINA O SALES DE LOS MISMOS; EN DONDE i) LA COMPOSICION NO COMPRENDE UN PEPTIDO DE MAS DE 20 RESTOS DE AMINOACIDOS DE LONGITUD, O SI UN PEPTIDO DE MAS DE 20 RESTOS DE AMINOACIDOS DE LONGITUD ESTA PRESENTE, EL PEPTIDO ESTA PRESENTE EN MENOS DEL 10 % EN PESO DEL PESO TOTAL DE LA COMPOSICION; ii) AL MENOS EL 50 % EN PESO DEL PESO TOTAL DE LA COMPOSICION ES UNA O MAS ENTIDADES DE AMINOACIDO EN FORMA LIBRE; Y iii) EL PORCENTAJE EN PESO DEL AMINOACIDO DE CITRULINA ES MAYOR QUE EL PORCENTAJE EN PESO DE LA N-ACETILCISTEINA. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE HEMOGLOBINOPATIA O UNA TALASEMIA TAL COMO ANEMIA DE CELULAS FALCIFORMES O BETA-TALASEMIA.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862687721P | 2018-06-20 | 2018-06-20 | |
US201962804879P | 2019-02-13 | 2019-02-13 | |
PCT/US2019/037925 WO2019246214A1 (en) | 2018-06-20 | 2019-06-19 | Compositions and methods for the treatment of hemoglobinopathies and thalassemias |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20210371A1 true PE20210371A1 (es) | 2021-02-26 |
Family
ID=67482969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020002097A PE20210371A1 (es) | 2018-06-20 | 2019-06-19 | Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias |
Country Status (20)
Country | Link |
---|---|
US (2) | US11058654B2 (es) |
EP (1) | EP3809881A1 (es) |
JP (1) | JP2021528414A (es) |
KR (1) | KR20210022054A (es) |
CN (1) | CN112654263A (es) |
AU (1) | AU2019290620A1 (es) |
BR (1) | BR112020026110A2 (es) |
CA (1) | CA3104279A1 (es) |
CL (1) | CL2020003276A1 (es) |
CU (1) | CU20200106A7 (es) |
EA (1) | EA202190073A1 (es) |
EC (1) | ECSP20081995A (es) |
IL (1) | IL279467A (es) |
JO (1) | JOP20200325A1 (es) |
MX (1) | MX2020013833A (es) |
PE (1) | PE20210371A1 (es) |
PH (1) | PH12020552212A1 (es) |
SG (1) | SG11202012714QA (es) |
TW (1) | TW202015667A (es) |
WO (1) | WO2019246214A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
JP2020517703A (ja) | 2017-04-28 | 2020-06-18 | アクセラ・ヘルス・インコーポレイテッドAxcella Health Inc. | アミノ酸組成物及び外傷性脳損傷の治療のためのそれらの使用 |
US10682325B2 (en) | 2017-08-14 | 2020-06-16 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
CU20200106A7 (es) | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
US11679089B2 (en) | 2018-06-20 | 2023-06-20 | Axcella Health Inc. | Methods of manufacturing amino acid compositions |
WO2021113762A1 (en) * | 2019-12-06 | 2021-06-10 | Axcella Health Inc. | Compositions and methods excluding or with reduced glutamine for the treatment of hemoglobinopathies and thalassemias |
CN112336710A (zh) * | 2020-12-27 | 2021-02-09 | 西北农林科技大学 | 谷氨酰胺在制备防治葛根素注射剂诱发的血管内溶血的药物上的应用 |
TW202315605A (zh) | 2021-07-26 | 2023-04-16 | 美商胺細拉健康公司 | 用於治療covid—19急性後期後遺症的胺基酸組合物及方法 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087398A (en) | 1996-03-01 | 2000-07-11 | South Alabama Medical Science Foundation | Sickle cell anemia treatment |
US5693671A (en) * | 1996-05-01 | 1997-12-02 | Harbor-Ucla Research And Education Institute | L-glutamine therapy for sickle cell diseases and thalassemia |
US6028107A (en) | 1997-02-27 | 2000-02-22 | Waugh; William Howard | Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection |
US6251927B1 (en) | 1999-04-20 | 2001-06-26 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
JP2004527501A (ja) | 2001-03-05 | 2004-09-09 | ピー. アーネスト,スティーヴン | 経腸処方 |
US7445807B2 (en) * | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
WO2004073623A2 (en) | 2003-02-14 | 2004-09-02 | Children's Hospital & Research Center At Oakland | Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
US20050070607A1 (en) | 2003-08-19 | 2005-03-31 | James Andrus | N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions |
JP2005272410A (ja) * | 2004-03-26 | 2005-10-06 | Ajinomoto Co Inc | 抗動脈硬化用及び/又は血液レオロジー改善用経口アミノ酸組成物 |
WO2006002096A2 (en) | 2004-06-18 | 2006-01-05 | Vivo Therapeutics, Inc. | Low doses of l-citrulline for treating diseases |
WO2006060793A2 (en) | 2004-12-01 | 2006-06-08 | Children's Hospital & Research Center At Oakland | Diagnosis of conditions associated with decreased arginine bioavailability |
WO2006116353A2 (en) | 2005-04-21 | 2006-11-02 | Goldstein Glenn | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
US20120316121A1 (en) | 2005-07-28 | 2012-12-13 | Allen Ann De Wees | Materials and Methods for Modulating Arginine Metabolism |
JP5316918B2 (ja) * | 2006-04-24 | 2013-10-16 | 味の素株式会社 | 透析患者用輸液剤 |
US20070286909A1 (en) | 2006-06-07 | 2007-12-13 | Daniel S. Smith | Amino acid compositions |
CA2668184A1 (en) * | 2006-10-31 | 2008-05-08 | Chrono Therapeutics, Inc. | Transdermal delivery techniques for drugs, nutraceuticals and other active substances |
CN100518815C (zh) * | 2007-02-15 | 2009-07-29 | 北京苏里曼医药科技有限公司 | 一种氨基酸组合物 |
CA2727088A1 (en) * | 2008-06-04 | 2009-12-10 | Phenolics, Llc | Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same |
US8840950B2 (en) | 2010-05-26 | 2014-09-23 | Jacqueline M. Hibbert | Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore |
US9040082B2 (en) | 2011-06-24 | 2015-05-26 | K-Pax Pharmaceuticals, Inc. | Compositions and methods for treatment of chronic fatigue |
WO2013072441A1 (en) | 2011-11-15 | 2013-05-23 | Tima Foundation | Composition for protection against cell-damaging effects |
RU2733396C2 (ru) | 2011-12-19 | 2020-10-01 | Иммаус Медикал, Инк. | Способы и композиции для лечения дивертикулеза |
US8980823B2 (en) | 2012-03-07 | 2015-03-17 | Shaker A. Mousa | Formulations of Factor VIIa inhibitors and utility |
US9597367B2 (en) * | 2013-04-19 | 2017-03-21 | Bioventures, Llc | Methods for improving muscle and heart function |
US11026913B2 (en) * | 2013-09-05 | 2021-06-08 | Emory University | Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto |
AU2014324901A1 (en) | 2013-09-25 | 2016-05-19 | Axcella Health Inc. | Compositions and formulations for prevention and treatment of diabetes and obesity, and methods of production and use thereof in glucose and caloric control |
US20180125926A1 (en) | 2013-09-25 | 2018-05-10 | Axcella Health Inc. | Compositions and Formulations and Methods of Production and Use Thereof |
WO2015106240A1 (en) | 2014-01-13 | 2015-07-16 | The General Hospital Corporation | Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin |
US20170056381A1 (en) * | 2014-02-20 | 2017-03-02 | Nanometics Llc | Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases |
MY189930A (en) * | 2014-04-30 | 2022-03-22 | Hoffmann La Roche | Glyt1 inhibitors for use in the treatment of hematological disorders |
MX2016015907A (es) | 2014-06-03 | 2018-08-01 | Sulfagenix Inc | Metodos y composiciones para tratar desordenes por deficiencia de oxido nitrico y condiciones relacionadas. |
WO2016033187A1 (en) | 2014-08-26 | 2016-03-03 | The Brigham And Women's Hospital, Inc. | Use of gelsolin in the treatment and diagnosis of sickle cell disease |
US9822190B2 (en) | 2015-01-29 | 2017-11-21 | Shaker A. Mousa | Compositions and method for anti-sickling of red blood cells in sickle cell disease |
AU2017306756B2 (en) | 2016-08-05 | 2022-10-27 | Fresenius Kabi Deutschland Gmbh | Glutamine for preserving, improving or restoring kidney function |
JOP20190147A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
AR111082A1 (es) | 2017-02-27 | 2019-05-29 | Univ Vanderbilt | Citrulina para el tratamiento de la crisis de células falciformes |
JP2020517703A (ja) | 2017-04-28 | 2020-06-18 | アクセラ・ヘルス・インコーポレイテッドAxcella Health Inc. | アミノ酸組成物及び外傷性脳損傷の治療のためのそれらの使用 |
BR112020002244A2 (pt) | 2017-08-14 | 2020-08-04 | Axcella Health Inc. | aminoácidos de cadeia ramificada para o tratamento de lesão neurológica |
US10682325B2 (en) | 2017-08-14 | 2020-06-16 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders associated with one or both of hyperammonemia or muscle wasting |
EP3810123A1 (en) | 2018-06-20 | 2021-04-28 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
CU20200106A7 (es) | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
US11679089B2 (en) | 2018-06-20 | 2023-06-20 | Axcella Health Inc. | Methods of manufacturing amino acid compositions |
MA52950A (fr) | 2018-06-20 | 2021-04-28 | Axcella Health Inc | Compositions pour thérapie et soin contenant des acides aminés ayant un goût amer |
WO2019246221A1 (en) | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of liver diseases and disorders |
-
2019
- 2019-06-16 CU CU2020000106A patent/CU20200106A7/es unknown
- 2019-06-19 WO PCT/US2019/037925 patent/WO2019246214A1/en unknown
- 2019-06-19 AU AU2019290620A patent/AU2019290620A1/en not_active Abandoned
- 2019-06-19 US US16/446,374 patent/US11058654B2/en active Active
- 2019-06-19 MX MX2020013833A patent/MX2020013833A/es unknown
- 2019-06-19 JP JP2020570705A patent/JP2021528414A/ja active Pending
- 2019-06-19 KR KR1020217001194A patent/KR20210022054A/ko unknown
- 2019-06-19 JO JOP/2020/0325A patent/JOP20200325A1/ar unknown
- 2019-06-19 EP EP19746553.7A patent/EP3809881A1/en active Pending
- 2019-06-19 SG SG11202012714QA patent/SG11202012714QA/en unknown
- 2019-06-19 CA CA3104279A patent/CA3104279A1/en not_active Abandoned
- 2019-06-19 EA EA202190073A patent/EA202190073A1/ru unknown
- 2019-06-19 BR BR112020026110-6A patent/BR112020026110A2/pt not_active Application Discontinuation
- 2019-06-19 CN CN201980054587.5A patent/CN112654263A/zh active Pending
- 2019-06-19 PE PE2020002097A patent/PE20210371A1/es unknown
- 2019-06-20 TW TW108121574A patent/TW202015667A/zh unknown
-
2020
- 2020-12-15 IL IL279467A patent/IL279467A/en unknown
- 2020-12-17 EC ECSENADI202081995A patent/ECSP20081995A/es unknown
- 2020-12-17 CL CL2020003276A patent/CL2020003276A1/es unknown
- 2020-12-18 PH PH12020552212A patent/PH12020552212A1/en unknown
-
2021
- 2021-06-08 US US17/341,716 patent/US20210290574A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20210022054A (ko) | 2021-03-02 |
JP2021528414A (ja) | 2021-10-21 |
US11058654B2 (en) | 2021-07-13 |
BR112020026110A2 (pt) | 2021-03-16 |
CN112654263A (zh) | 2021-04-13 |
CU20200106A7 (es) | 2021-08-06 |
ECSP20081995A (es) | 2021-01-29 |
EP3809881A1 (en) | 2021-04-28 |
CA3104279A1 (en) | 2019-12-26 |
WO2019246214A8 (en) | 2020-02-20 |
US20210290574A1 (en) | 2021-09-23 |
WO2019246214A1 (en) | 2019-12-26 |
SG11202012714QA (en) | 2021-01-28 |
EA202190073A1 (ru) | 2021-04-12 |
PH12020552212A1 (en) | 2021-08-16 |
JOP20200325A1 (ar) | 2020-12-14 |
TW202015667A (zh) | 2020-05-01 |
AU2019290620A1 (en) | 2021-01-14 |
CL2020003276A1 (es) | 2021-07-09 |
MX2020013833A (es) | 2021-03-25 |
IL279467A (en) | 2021-01-31 |
US20190388376A1 (en) | 2019-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20210371A1 (es) | Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias | |
ES2555257T3 (es) | Fórmula infantil baja en proteínas con aumento de los aminoácidos esenciales | |
PE20191136A1 (es) | Composiciones de aminoacidos y metodos de tratamiento de enfermedades hepaticas | |
CY1124262T1 (el) | Σκευασματα βενδαμουστινης | |
BR112013020609A2 (pt) | 2-hidróxi-4-(metiltio) butironitrila estável em armazenamento | |
AR093792A1 (es) | Composiciones que contienen zinc estables al fluoruro | |
AR084362A1 (es) | Amidas de aminoindano que tienen una alta actividad fungicida y sus composiciones fitosanitarias | |
EA201690623A1 (ru) | Простациклиновые соединения, композиции и способы их использования | |
MA31998B1 (fr) | Nouveaux derives d'insuline ayant un profil temps-action extremement retarde | |
PA8774901A1 (es) | Productos de cuidado oral y metodos para usar y fabricar el mismo | |
RU2011129605A (ru) | Применение азотсодержащих аналогов куркумина для лечения болезни альцгеймера | |
PE20141676A1 (es) | Composiciones de yodo-povidona estable | |
AR100685A1 (es) | Amidas / ésteres de bajo peso molecular que contienen sales de amonio cuaternario | |
AR067701A1 (es) | Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2 | |
FI3777833T3 (fi) | Dopa-dekarboksylaasin estäjän koostumuksia | |
BR112012018023A2 (pt) | formulações líquidas que contêm anticorpo estabilizado. | |
AR081724A1 (es) | Composicion herbicida que contiene los hidratos de saflufenacilo y glifosato o glufosinato | |
ECSP11011121A (es) | Sales de fingolimod | |
AR079890A1 (es) | Estabilizacion de peliculas de oxido de zinc en composiciones bucales | |
AR088766A1 (es) | Composicion farmaceutica que comprende rasagilina | |
Sase et al. | Changes of hippocampal beta-alanine and citrulline levels are paralleling early and late phase of retrieval in the Morris Water Maze | |
AR089269A1 (es) | Composiciones para el cuidado oral | |
AR075097A1 (es) | Sales y formas polimorficas cristalinas de [4-(6-fluoro-7-metilamino-2,4-dioxo-1,4-dihidro-2h-quinazolin-3-il)-fenil]-5-cloro-tiofen-2-il-sulfonil urea, composiciones farmaceuticas que las contiene, metodo para prepararlas y uso de las mismas en el tratamiento de enfermedades cardiovasculares asocia | |
CR20130181A (es) | UNA COMPOSICIÓN QUE COMPRENDE 2-metilpropanotioato de S-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] Y CROSCARMELOSA SODICA | |
UY33568A (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes. |